Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Outcomes and Treatment Patterns of Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223 Concomitantly With Abiraterone or Enzalutamide in First Line Setting : A Retrospective Chart Abstraction Study

Trial Profile

Outcomes and Treatment Patterns of Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223 Concomitantly With Abiraterone or Enzalutamide in First Line Setting : A Retrospective Chart Abstraction Study

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Radium 223 chloride (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 29 Oct 2018 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
    • 31 Aug 2018 Biomarkers information updated
    • 12 Aug 2018 Planned End Date changed from 31 Jul 2018 to 28 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top